On June 14, a paper titled, “Direct-to-consumer Marketing to People with Hemophilia,” was published in the online journal, PLOS Medicine. I’d like to take this opportunity to address a few issues. First, under no circumstances does the National Hemophilia Foundation (NHF) recommend particular treatments for specific individuals. Rather, we encourage people with bleeding disorders to consult with their physician or local treatment center before pursuing any course of treatment. Second, I can vouch for the appreciation that our community feels for the companies discovering and developing their therapies and ultimately, their cures, and the programs and initiatives they and our other donors make possible without influence. Third, we never have and never will advocate for any single treatment or group of treatments before legislators, or public and private payers. Instead, NHF advocates for all FDA-approved therapies, and will continue to fight to ensure that individuals with bleeding disorders have access to the therapies they need.
Val D. Bias
CEO
National Hemophilia Foundation
